KR20230004644A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR20230004644A
KR20230004644A KR1020227039987A KR20227039987A KR20230004644A KR 20230004644 A KR20230004644 A KR 20230004644A KR 1020227039987 A KR1020227039987 A KR 1020227039987A KR 20227039987 A KR20227039987 A KR 20227039987A KR 20230004644 A KR20230004644 A KR 20230004644A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
total weight
api
amount
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039987A
Other languages
English (en)
Korean (ko)
Inventor
쩌렌 왕
준 슈
피터 파리나
슌 첸
šœ 첸
Original Assignee
선전 파마신 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선전 파마신 컴퍼니 리미티드 filed Critical 선전 파마신 컴퍼니 리미티드
Publication of KR20230004644A publication Critical patent/KR20230004644A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227039987A 2020-04-17 2021-04-16 약제학적 조성물 Pending KR20230004644A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/085241 2020-04-17
CN2020085241 2020-04-17
PCT/CN2021/087690 WO2021209025A1 (en) 2020-04-17 2021-04-16 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR20230004644A true KR20230004644A (ko) 2023-01-06

Family

ID=78084668

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039987A Pending KR20230004644A (ko) 2020-04-17 2021-04-16 약제학적 조성물

Country Status (8)

Country Link
US (1) US20230128252A1 (https=)
EP (1) EP4135699A4 (https=)
JP (1) JP2023522065A (https=)
KR (1) KR20230004644A (https=)
CN (1) CN115135323A (https=)
AU (1) AU2021255559A1 (https=)
CA (1) CA3180160A1 (https=)
WO (1) WO2021209025A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
CN116115563B (zh) * 2023-03-30 2023-08-29 石家庄四药有限公司 一种氟比洛芬混悬注射液及其制备方法
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions
CN117731649B (zh) * 2023-12-21 2025-01-28 博济医药科技股份有限公司 一种氨甲环酸药物组合物及其制备工艺
CN119837856A (zh) * 2024-12-11 2025-04-18 江南大学 一种具有预防和改善特应性皮炎的黄酮组合物及其应用
CN120865107B (zh) * 2025-09-22 2026-01-23 中国医学科学院医药生物技术研究所 一种苯吩嗪衍生物、其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814814C2 (de) * 1998-04-02 2002-01-31 Gerhard Steffan Wasserlösliche, Iminophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US10179159B2 (en) * 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
CA2775393C (en) * 2012-05-02 2014-04-29 Samy Saad Topical non-aqueous pharmaceutical formulations
US8852648B2 (en) * 2012-11-06 2014-10-07 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
CN105492004A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗局部微生物感染的方法
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN105693668A (zh) * 2016-04-23 2016-06-22 贺玉皓 一种氯法齐明的药物组合物及其医药用途

Also Published As

Publication number Publication date
WO2021209025A1 (en) 2021-10-21
AU2021255559A1 (en) 2022-11-17
JP2023522065A (ja) 2023-05-26
US20230128252A1 (en) 2023-04-27
EP4135699A4 (en) 2024-05-01
EP4135699A1 (en) 2023-02-22
CA3180160A1 (en) 2021-10-21
CN115135323A (zh) 2022-09-30

Similar Documents

Publication Publication Date Title
US20230128252A1 (en) Pharmaceutical compositions
TWI847974B (zh) 包含托法替尼的局部配方
JP6246834B2 (ja) カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
US9415108B2 (en) Compositions for transdermal delivery of active agents
AU2017290710A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
JP2005518354A (ja) コドラッグを含有する医薬組成物
JP2012507511A (ja) 少なくとも２種の透過増強剤を組み合わせて含む局所用組成物
US20240245713A1 (en) Long-acting injectable formulations and use thereof
US20250249009A1 (en) New topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
KR20120118495A (ko) 국부 마취제 에멀전 조성물 및 이의 제조 및 사용 방법
TWI729371B (zh) 治療搔癢症的組合物與方法
TWI510243B (zh) 用於治療膀胱癌的組成物及方法
CN106376232A (zh) 用于持续释放癸二酰二纳布啡酯的药物制剂
EP4440546A1 (en) Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
WO2023102559A1 (en) Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
US20050158371A1 (en) Novel external agent
JP5897299B2 (ja) ローション剤
WO2020222192A1 (en) Methods of treating pruritus
WO2016052617A1 (ja) ナルフラフィン含有局所適用製剤
CN115279788A (zh) 用于治疗银屑病和其他疾病的外用环孢霉素

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902